Aaron Ondrey is Chief Financial Officer for Rocket Pharma, leading the company’s Finance, Investor Relations, and Corporate Communications functions. Aaron is a seasoned finance executive with more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions across multiple therapeutic areas.
Previously, Aaron served as CFO of Mirati Therapeutics, overseeing all aspects of Finance, IT, and Facilities through the launch of KRAZATI® and the company’s acquisition by Bristol Myers Squibb in January 2024. Prior to joining Mirati as Senior Vice President, FP&A in July of 2022, Aaron was the Vice President, Finance, at Arena Pharmaceuticals and oversaw FP&A, Corporate Planning and Strategic sourcing.
Prior to Arena, Aaron served as the Head of U.S. and Global Commercial Finance at Alexion Pharmaceuticals with responsibility for financial management of approximately $5 billion in revenue across more than 50 countries. He previously held leadership positions of increasing responsibility supporting multiple product launches at Regeneron Pharmaceuticals, most recently as Head of Commercial Finance, Business Planning. Aaron received a Bachelor of Sciences in finance from Case Western Reserve University.
In his spare time, Aaron enjoys spending time with his family, including his wife, three kids and three dogs. He is an avid soccer fan and loves to cook. Sunday morning pancakes and midnight noodles are family favorites. Aaron balances his time between the countryside of Connecticut and the coast of Maine.
What is Aaron Ondrey's net worth?
The estimated net worth of Aaron Ondrey is at least $438.35 thousand as of July 3rd, 2025. Ondrey owns 128,173 shares of Rocket Pharmaceuticals stock worth more than $438,352 as of December 5th. This net worth estimate does not reflect any other assets that Ondrey may own. Learn More about Aaron Ondrey's net worth.
How old is Aaron Ondrey?
Ondrey is currently 47 years old. There are 5 older executives and no younger executives at Rocket Pharmaceuticals. The oldest executive at Rocket Pharmaceuticals is Mr. Jonathan Schwartz M.D., Chief Medical & Gene Therapy Officer, who is 59 years old. Learn More on Aaron Ondrey's age.
How do I contact Aaron Ondrey?
Has Aaron Ondrey been buying or selling shares of Rocket Pharmaceuticals?
Aaron Ondrey has not been actively trading shares of Rocket Pharmaceuticals during the last ninety days. Most recently, Aaron Ondrey sold 1,477 shares of the business's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $2.88, for a transaction totalling $4,253.76. Following the completion of the sale, the chief financial officer now directly owns 128,173 shares of the company's stock, valued at $369,138.24. Learn More on Aaron Ondrey's trading history.
Who are Rocket Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Rocket Pharmaceuticals?
During the last year, Rocket Pharmaceuticals insiders bought shares 3 times. They purchased a total of 51,099 shares worth more than $234,865.30. During the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 74,948 shares worth more than $279,986.45. The most recent insider tranaction occured on October, 14th when insider John Militello sold 28,918 shares worth more than $114,515.28. Insiders at Rocket Pharmaceuticals own 24.8% of the company.
Learn More about insider trades at Rocket Pharmaceuticals. Information on this page was last updated on 10/14/2025.
